Azora Therapeutics, Inc. Common Stock (AZR)

• Market cap: $10M
• 1 day: -21.93%
• 5 days: -15.33%
• 1 month: -21.93%
• 3 months: -21.93%
• 6 months: -21.93%
• Year to date: -21.93%
• 1 year: -21.93%
• 5 years: -21.93%
• 10 years: -21.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Azora Therapeutics Inc is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. Azora owns the royalty-free rights to its technology, which is based on the development of potential best-in-class oral agonists of the aryl hydrocarbon receptor. Azora's lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis.

Employees: 6